

12th May 2023

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor
Plot no. C/1, G Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II
L-1840 Luxembourg</p> | |

Sub: Disclosure of related party transactions for the half-year ended 31st March 2023

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the disclosure of related party transactions, for the half-year ended 31st March 2023.

The disclosure is also being uploaded on the website of the Company: www.cipla.com.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**

Rajendra Chopra
Company Secretary

Encl.: as above

Prepared by: Y. Navya Sri Swathi

Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
	Details of the counterparty					Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	
210	Meditab Specialities Limited		Sitec Labs Limited		Subsidiaries	Any other transaction	Testing and Analysis Charges	-	Not Applicable	0.00	-	-									
211	Medispray Laboratories Private Limited		Sitec Labs Limited		Subsidiaries	Any other transaction	Testing and Analysis Charges	-	Not Applicable	0.01	-	-									
212	Sitec Labs Limited		Medispray Laboratories Private Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.15	0.01									
213	Cipla Pharma and Life Sciences Limited		Medispray Laboratories Private Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.01	-									
214	Cipla Maroc S.A.		Medispray Laboratories Private Limited		Subsidiaries	Purchase of goods or services		-	Not Applicable	0.86	-	-									
215	Sitec Labs Limited		Goldencross Pharma Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.00	-									
216	Cipla Health Limited		Goldencross Pharma Limited		Subsidiaries	Purchase of goods or services		-	Not Applicable	8.08	-	-									
217	Goldencross Pharma Limited		Cipla Health Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.19	0.09									
218	Sitec Labs Limited		Cipla Health Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.01	0.02									
219	Cipla Health Limited		Sitec Labs Limited		Subsidiaries	Any other transaction	Testing and Analysis Charges	-	Not Applicable	0.01	-	-									
220	Sitec Labs Limited		Cipla Quality Chemical Industries Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.00	0.00									
221	Cipla USA Inc.		Sitec Labs Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.22	0.22									
222	Sitec Labs Limited		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.19	2.02									
223	InvaGen Pharmaceuticals Inc		Sitec Labs Limited		Subsidiaries	Purchase of goods or services		-	Not Applicable	2.00	-	-									
224	Sitec Labs Limited		Cipla (Jiangsu) Pharmaceutical Co. Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.78	1.81									
225	Cipla (Jiangsu) Pharmaceutical Co. Limited		Sitec Labs Limited		Subsidiaries	Any other transaction	Testing and Analysis Charges	-	Not Applicable	1.93	-	-									
226	Cipla Medpro Botswana Proprietary Limited		Medpro Pharmaceutica (Pty) Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.00	0.00									
227	Cipla Quality Chemical Industries Limited		Medpro Pharmaceutica (Pty) Limited		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	0.01	-	-									
228	Medpro Pharmaceutica (Pty) Limited		Cipla Quality Chemical Industries Limited		Subsidiaries	Purchase of goods or services		-	Not Applicable	4.17	-	-									
229	Medpro Pharmaceutica (Pty) Limited		Cipla Quality Chemical Industries Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.03	0.04									
230	Cipla Quality Chemical Industries Limited		Medpro Pharmaceutica (Pty) Limited		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	-	4.10									
231	Cipla Technologies LLC		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	0.41	-	-									
232	Cipla USA Inc.		Cipla Technologies LLC		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.51	0.07									
233	Cipla USA Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	213.68	173.90									
234	Cipla USA Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Purchase of goods or services		-	Not Applicable	316.56	-	-									
235	InvaGen Pharmaceuticals Inc		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	7.78	-	-									
236	Cipla USA Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	83.32	-	-									
237	Exelan Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	0.69	-	-									
238	Cipla USA Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.00	0.69									
239	Cipla Therapeutics Inc		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	0.08	-	-									
240	Meditab Holdings Limited		Cipla Kenya Limited		Subsidiaries	Loan		-	Not Applicable	-	20.34	20.54			Loan	0.00%	Payable on Demand	Unsecured	Business purpose		
241	Meditab Holdings Limited		Medpro Pharmaceutica (Pty) Limited		Subsidiaries	Loan		-	Not Applicable	-	90.93	-			Loan	6 months USD LIBOR + 0.2%	3 Years	Unsecured	Business purpose		
242	Medpro Pharmaceutica (Pty) Limited		Meditab Holdings Limited		Subsidiaries	Interest paid		-	Not Applicable	2.24	-	-									
243	Cipla USA Inc.		Aspergen Inc		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	3.76	5.17									
244	Aspergen Inc.		Cipla USA Inc.		Subsidiaries	Purchase of goods or services		-	Not Applicable	1.37	-	-									
245	Cipla USA Inc.		Cipla Gulf FZ-LLC		Subsidiaries	Purchase of goods or services		-	Not Applicable	0.21	-	-									
246	Cipla Gulf FZ-LLC		Cipla USA Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	-	0.21									
247	InvaGen Pharmaceuticals Inc		Cipla Technologies LLC		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	4.70	-	-									
248	Cipla Technologies LLC		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	25.36	30.32									
249	InvaGen Pharmaceuticals Inc		Cipla Technologies LLC		Subsidiaries	Investment		-	Not Applicable	32.89	-	-									
250	Exelan Pharmaceuticals Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Purchase of goods or services		-	Not Applicable	334.34	-	-									
251	Exelan Pharmaceuticals Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	12.98	-	-									
252	InvaGen Pharmaceuticals Inc		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	300.75	264.11									
253	InvaGen Pharmaceuticals Inc		Cipla Therapeutics Inc.		Subsidiaries	Investment		-	Not Applicable	16.39	-	-									
254	InvaGen Pharmaceuticals Inc		Cipla (China) Pharmaceutical Co., Ltd		Subsidiaries	Any other transaction	Reimbursement Charges Paid	-	Not Applicable	0.78	-	-									
255	Cipla (China) Pharmaceutical Co., Ltd		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other receivable	-	Not Applicable	-	0.76	-									
256	Cipla Maroc S.A.		Cipla (EU) Limited		Subsidiaries	Interest paid		-	Not Applicable	0.08	-	-									
257	Cipla (EU) Limited		Cipla Maroc S.A.		Subsidiaries	Loan		-	Not Applicable	-	3.42	3.81			Loan	5.01%	1 Year	Unsecured	Business purpose		

Sr No.	Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	
489	Cipla Limited		Deepak Rodrigues .		Key Management Personnel of Subsidiary	Remuneration		0.32	Approved	0.15	-	-									
490	Cipla Limited		Ijaz Khalif		Key Management Personnel of Subsidiary	Remuneration		1.08	Approved	0.22	-	-									
491	Cipla Limited		Sunil V Patil		Key Management Personnel of Subsidiary	Remuneration		0.04	Approved	0.04	-	-									
492	Cipla Limited		Juzer Yusuf Masta		Key Management Personnel of Subsidiary	Remuneration		0.11	Approved	0.04	-	-									
493	Cipla Limited		Chandru Chawla		Key Management Personnel of Subsidiary	Remuneration		3.27	Approved	1.99	-	-									
494	Cipla Limited		Dr Peter Mugenyi		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.35	-	-									
495	Cipla Limited		Dr Y K Hamied		Non-executive Chairman	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	1.05	-	-									
496	Cipla Limited		Mr Adil Zainulbhai		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.33	-	-									
497	Cipla Limited		Mr Ashok Sinha		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.37	-	-									
498	Cipla Limited		Mr M K Hamied		Non-executive Vice-Chairman	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	1.04	-	-									
499	Cipla Limited		Mr S Radhakrishnan		Non-executive director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	1.10	-	-									
500	Cipla Limited		Ms Punita Lal		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.32	-	-									
501	Cipla Limited		Mr Robert Stewart		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.37	-	-									
502	Cipla Limited		Dr Mandar Vaidya		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.30	-	-									
503	Cipla Limited		Mr P R Ramesh		Non-Executive Independent director	Any other transaction	Commission and other benefits	-	As per approval of Board of Directors or Shareholders as necessary	0.34	-	-									
504	Cipla Limited		Gaurav Datay		Key Management Personnel of Subsidiary	Advance		-	Not Applicable	-	0.15	-									
505	Cipla Limited		Mr Ashok Sinha		Non-Executive Independent director	Any other transaction	Commission and other benefits payable	-	Not Applicable	-	0.30	-									
506	Cipla Limited		Umang Vohra		Key Management Personnel	Remuneration		-	As per approval of Board of Directors or Shareholders as necessary	1.85	-	-									
507	Cipla Limited		Samina Hamied		Key Management Personnel	Remuneration		-	As per approval of Board of Directors or Shareholders as necessary	2.07	-	-									
508	Cipla Limited		Ashish Adukia		Key Management Personnel	Remuneration		-	As per approval of Board of Directors or Shareholders as necessary	1.75	-	-									
509	Cipla Limited		Rajendra Chopra		Key Management Personnel	Remuneration		-	As per approval of Board of Directors or Shareholders as necessary	0.86	-	-									
510	Cipla Medica Pharmaceutical and Chemical Industries Limited		Al Jabal Drugs And Medical Appliances Dmcc		The entity is controlled or jointly controlled by KMP or close relatives of KMP of subsidiary	Any other transaction	Trade and other payables	-	Not applicable	-	1.38	-									
511	Medispray Laboratories Private Limited		The Pharmaceutical Institute		Related party of subsidiary	Sale of goods or services		-	Not applicable	0.73	-	-									
512	Medispray Laboratories Private Limited		The Pharmaceutical Institute		Related party of subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable	-	0.47	0.34									
513	Cipla (EU) Limited		Cipla (Ilangsu) Pharmaceutical Co. Limited		Subsidiaries	Loan		-	Not applicable	36.00	-	-									
514	Cipla Kenya Limited		Joan Wakori		Key Management Personnel of Subsidiary	Remuneration		-	Not applicable	0.60	-	-									
515	Medpro Pharmaceutica (Pty) Limited		Genevieve Mannel		Key Management Personnel of Subsidiary	Remuneration		-	Not applicable	0.54	-	-									
516	Invagen Pharmaceuticals Inc		Rohit Mehta		Key Management Personnel of Subsidiary	Remuneration		-	Not applicable	0.03	-	-									

Notes:

- 1 Expenses towards gratuity, compensated absences and premium paid for group health insurance has not been considered in above information as separate actuarial valuation/premium paid are not available.
- 2 Remuneration reported pertains to the amount paid during the period including variable pay of previous year, ESOP/ESAR exercised during the six months ended 31st March, 2023 but does not include provisions towards variable pay, share based payment expenses as per Ind AS 102 etc.
- 3 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors of Cipla Limited, as applicable, for financial year 2022-23.
- 4 Amount mentioned as "0.00" denotes value less than ₹ 50,000.